



## Clinical trial results:

### **Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on tumor necrosis factor alpha (TNF) antaGoNists: A clinical Trial Evaluating Treatment REsults**

#### **Summary**

EudraCT number	2013-001855-11
Trial protocol	GB IE
Global end of trial date	12 July 2016

#### **Results information**

Result version number	v1 (current)
This version publication date	02 February 2018
First version publication date	02 February 2018

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	CAIN457AGB01
-----------------------	--------------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01961609
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 4163241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 4163241111,

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 July 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 July 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study is to evaluate the efficacy of secukinumab (300mg) treatment with respect to PASI 75 response rate after 16 weeks treatment, by assessing the percentage (%) of patients achieving PASI 75 after 16 weeks compared to baseline (defined as PASI status at Week 0).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Ireland: 12
Country: Number of subjects enrolled	United Kingdom: 223
Worldwide total number of subjects	235
EEA total number of subjects	235

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	223
From 65 to 84 years	12



## Subject disposition

### Recruitment

Recruitment details:

This study consisted of 3 periods: initiation, maintenance 1 and maintenance 2. During the initiation period, participants received secukinumab 150 mg or 300 mg for 16 weeks.

### Pre-assignment

Screening details:

For both maintenance periods 1 and 2, after 16 weeks and 48 weeks, respectively, responders at both the 150 mg and 300 mg doses continued on their initiation doses during maintenance periods 1 and 2. Non-responders at 150 mg were uptitrated to 300 mg. Non-responders at 300 mg returned to routine treatment under the care of their usual clinician.

### Period 1

Period 1 title	Initiation (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Secukinumab (AIN457) 300 mg

Arm description:

Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the National Institute for Health and Care Excellence (NICE) criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.

Arm type	Experimental
Investigational medicinal product name	Secukinumab
Investigational medicinal product code	AIN457
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the National Institute for Health and Care Excellence (NICE) criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.

<b>Arm title</b>	Secukinumab (AIN457) 150 mg
------------------	-----------------------------

**Arm description:**

Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg at the discretion of the treating physician. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg at the discretion of the treating physician.

Arm type	Experimental
Investigational medicinal product name	Secukinumab
Investigational medicinal product code	AIN457
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg at the discretion of the treating physician. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg at the discretion of the treating physician.

<b>Number of subjects in period 1</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg
Started	119	116
Safety set	118	115
Full analysis set	118	115
Completed	107	103
Not completed	12	13
Adverse event, serious fatal	-	1
Consent withdrawn by subject	1	2
Adverse event, non-fatal	3	5
Randomized but not treated	1	1
Protocol deviation	1	-
Administrative problems	1	-
Abnormal lab values	-	1
Missing	3	2
Lack of efficacy	2	1



## Baseline characteristics

### Reporting groups

Reporting group title	Secukinumab (AIN457) 300 mg
-----------------------	-----------------------------

Reporting group description:

Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the National Institute for Health and Care Excellence (NICE) criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.

Reporting group title	Secukinumab (AIN457) 150 mg
-----------------------	-----------------------------

Reporting group description:

Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg at the discretion of the treating physician. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg at the discretion of the treating physician.

Reporting group values	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Total
Number of subjects	119	116	235
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	114	109	223
From 65-84 years	5	7	12
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	46.6	44.6	
standard deviation	± 11.63	± 11.73	-
Gender, Male/Female Units: Subjects			
Female	51	52	103
Male	68	64	132

## End points

### End points reporting groups

Reporting group title	Secukinumab (AIN457) 300 mg
-----------------------	-----------------------------

Reporting group description:

Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the National Institute for Health and Care Excellence (NICE) criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.

Reporting group title	Secukinumab (AIN457) 150 mg
-----------------------	-----------------------------

Reporting group description:

Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg at the discretion of the treating physician. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg at the discretion of the treating physician.

Subject analysis set title	Secukinumab (AIN457) 300 mg subgroup 1
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants who had experienced an IR after trying the first anti-tumor necrosis factor-alpha (TNFalpha) therapy

Subject analysis set title	Secukinumab (AIN457) 300 mg subgroup 2
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants who had initially experienced an adequate response after trying the first TNFalpha therapy, but then subsequently lost that response

Subject analysis set title	Secukinumab (AIN457) 300 mg subgroup 3
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All participants who have tried and failed more than one anti-TNFalpha therapies

Subject analysis set title	Secukinumab (AIN457) 150 mg subgroup 1
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants who had experienced an IR after trying the first anti-tumor necrosis factor-alpha (TNFalpha) therapy

Subject analysis set title	Secukinumab (AIN457) 150 mg subgroup 2
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants who had initially experienced an adequate response after trying the first TNFalpha therapy, but then subsequently lost that response

Subject analysis set title	Secukinumab (AIN457) 150 mg subgroup 3
----------------------------	--

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All participants who have tried and failed more than one anti-TNFalpha therapies

Subject analysis set title	Secukinumab (AIN457A) 300 mg subgroups 1 and 2 combined
----------------------------	---

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants who experienced an IR after trying first anti-TNFalpha therapy and participants who had initially experienced an adequate response after trying the first anti-TNFalpha therapy but then had

subsequently lost that response.

Subject analysis set title	Secukinumab (AIN457) 150 mg subgroups 1 and 2 combined
Subject analysis set type	Full analysis

Subject analysis set description:

Participants who experienced an IR after trying first anti-TNFalpha therapy and participants who had initially experienced an adequate response after trying the first anti-TNFalpha therapy but then had subsequently lost that response.

Subject analysis set title	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)
Subject analysis set type	Full analysis

Subject analysis set description:

Non-responders at secukinumab 150mg from the initiation period were uptitrated to secukinumab 300 mg at week 16.

Subject analysis set title	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 2)
Subject analysis set type	Full analysis

Subject analysis set description:

Non-responders at secukinumab 150 mg from maintenance 1 period were uptitrated to secukinumab 300 mg at week 48.

### **Primary: Percentage of secukinumab 300 mg participants achieving PASI 75 at 16 weeks**

End point title	Percentage of secukinumab 300 mg participants achieving PASI 75 at 16 weeks <sup>[1][2]</sup>
-----------------	---

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq 75\%$  improvement from baseline.

End point type	Primary
----------------	---------

End point timeframe:

16 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis applies to the Secukinumab (AIN457) 300 mg group only.

Non-inferiority/equivalence test = No

P-Value: <0.0001

Method of estimation: 2-sided binomial exact test

Estimated value: 65.3 percent (A Bonferroni adjustment adjusting for 8 analyses have been applied.)

99.375% Confidence interval, 2-sided: 52.4 to 76.7

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: All arms do not apply to this end point.

<b>End point values</b>	Secukinumab (AIN457) 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: Percentage of participants				
number (not applicable)	65.3			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of secukinumab 150 mg participants achieving PASI 75 at 16 weeks

End point title	Percentage of secukinumab 150 mg participants achieving PASI 75 at 16 weeks <sup>[3]</sup>
-----------------	--

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq 75\%$  improvement from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

16 Weeks

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: All arms do not apply to this end point.

<b>End point values</b>	Secukinumab (AIN457) 150 mg			
Subject group type	Reporting group			
Number of subjects analysed	115			
Units: Percentage of participants				
number (not applicable)	44.3			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants achieving PASI 75 according to 3 key participant subgroups (Primary Inadequate Response (IR), Secondary IR and IR after more than one anti-TNFalpha therapies) at 16 weeks

End point title	Percentage of participants achieving PASI 75 according to 3 key participant subgroups (Primary Inadequate Response (IR), Secondary IR and IR after more than one anti-TNFalpha therapies) at 16 weeks
-----------------	---

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and

desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq 75\%$  improvement from baseline.

End point type	Secondary
End point timeframe:	
16 Weeks	

End point values	Secukinumab (AIN457) 300 mg subgroup 1	Secukinumab (AIN457) 300 mg subgroup 2	Secukinumab (AIN457) 300 mg subgroup 3	Secukinumab (AIN457) 150 mg subgroup 1
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	44	44	18
Units: Percentage of participants				
number (not applicable)	71.4	70.5	47.7	38.9

End point values	Secukinumab (AIN457) 150 mg subgroup 2	Secukinumab (AIN457) 150 mg subgroup 3		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	42	37		
Units: Percentage of participants				
number (not applicable)	61.9	32.4		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants achieving PASI 75 - Initiation Period

End point title	Percentage of participants achieving PASI 75 - Initiation Period
-----------------	--

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq 75\%$  improvement from baseline.

End point type	Secondary
End point timeframe:	
2 ,4, 8, 12 and 16 Weeks	

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	115		
Units: Percentage of participants				
number (not applicable)				
Week 2	1.7	2.6		
Week 4	27.1	18.3		
Week 8	60.2	40.0		
Week 12	61.9	52.2		
Week 16	65.3	44.3		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants achieving PASI 75 - Maintenance 1 Period

End point title	Percentage of participants achieving PASI 75 - Maintenance 1 Period
-----------------	---

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq$  75% improvement from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

16, 24 and 48 Weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	107	66	37	
Units: Percentage of participants				
number (not applicable)				
Week 16	72.0	75.8	2.7	
Week 24	61.7	68.2	13.5	
Week 48	52.3	39.4	8.1	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants achieving PASI 75 - Maintenance 2 Period

End point title	Percentage of participants achieving PASI 75 - Maintenance 2 Period
-----------------	---

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq 75\%$  improvement from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

48 and 72 Weeks

End point values	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 2)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	83	31	16	24
Units: Percentage of participants				
number (not applicable)				
Week 48	65.1	80.6	18.8	4.2
Week 72	65.1	58.1	25.0	37.5

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants achieving PASI 50 and PASI 90 - Initiation Period

End point title	Percentage of participants achieving PASI 50 and PASI 90 - Initiation Period
-----------------	--

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50 and PASI 90 are defined as participants achieving  $\geq 50\%$  and  $\geq 90\%$  improvement from baseline, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

2, 4, 8, 12, 16 Weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	115		
Units: Percentage of participants				
number (not applicable)				
PASI 50, week 2	28.0	25.2		
PASI 50, week 4	63.6	57.4		
PASI 50, week 8	84.7	67.8		
PASI 50, week 12	82.2	69.6		
PASI 50, week 16	82.2	65.2		
PASI 90, week 2	0	0		
PASI 90, week 4	6.8	4.3		
PASI 90, week 8	25.4	20.0		
PASI 90, week 12	38.1	25.2		
PASI 90, week 16	41.5	20.0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants achieving PASI 50 and PASI 90 - Maintenance 1 Period

End point title	Percentage of participants achieving PASI 50 and PASI 90 - Maintenance 1 Period
-----------------	---

End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50 and PASI 90 are defined as participants achieving  $\geq 50\%$  and  $\geq 90\%$  improvement from baseline, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

16, 24 and 48 Weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	107	66	37	
Units: Percentage of participants				

number (not applicable)				
PASI 50, week 16	89.7	95.5	24.3	
PASI 50, week 24	80.4	89.4	54.1	
PASI 50, week 48	70.1	65.2	32.4	
PASI 90, week 16	45.8	34.8	0	
PASI 90, week 24	39.3	37.9	2.7	
PASI 90, week 48	31.8	18.2	5.4	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants achieving PASI 50 and PASI 90 - Maintenance 2 Period

End point title	Percentage of participants achieving PASI 50 and PASI 90 - Maintenance 2 Period
End point description:	
<p>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50 and PASI 90 are defined as participants achieving <math>\geq 50\%</math> and <math>\geq 90\%</math> improvement from baseline, respectively.</p>	
End point type	Secondary
End point timeframe:	
48 and 72 Weeks	

End point values	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 2)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	83	31	16	24
Units: Percentage of participants				
number (not applicable)				
PASI 50, week 48	88.0	96.8	75.0	50.0
PASI 50, week 72	74.7	80.6	37.5	70.8
PASI 90, week 48	41.0	38.7	12.5	0
PASI 90, week 72	38.6	22.6	18.8	16.7

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants who have failed on one anti-TNF $\alpha$ achieving

## PASI 75 (subgroups 1 and 2 combined) at 16 weeks

End point title	Percentage of participants who have failed on one anti-TNF $\alpha$ achieving PASI 75 (subgroups 1 and 2 combined) at 16 weeks
-----------------	--

### End point description:

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 is defined as participants achieving  $\geq$  75% improvement from baseline.

End point type	Secondary
----------------	-----------

### End point timeframe:

16 Weeks

End point values	Secukinumab (AIN457A) 300 mg subgroups 1 and 2 combined	Secukinumab (AIN457) 150 mg subgroups 1 and 2 combined		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	58	60		
Units: Percentage of participants				
number (not applicable)	70.7	55.0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants achieving NICE continuation criteria (PASI 75 or PASI 50 plus a 5 point improvement in DLQI) at 16 weeks

End point title	Percentage of participants achieving NICE continuation criteria (PASI 75 or PASI 50 plus a 5 point improvement in DLQI) at 16 weeks
-----------------	---

### End point description:

PASI 75 is defined as participants achieving  $\geq$  75% improvement from baseline. The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases. The measure is widely used: it has been tested across 32 different skin conditions and is available in 55 languages. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

End point type	Secondary
----------------	-----------

### End point timeframe:

16 Weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	115		
Units: Percentage of participants				
number (not applicable)	81.4	60.9		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean change from baseline in Dermatology Life Quality Index (DLQI)Total scores - Initiation Period

End point title	Mean change from baseline in Dermatology Life Quality Index (DLQI)Total scores - Initiation Period
-----------------	--

End point description:

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases. The measure is widely used: it has been tested across 32 different skin conditions and is available in 55 languages. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative change from baseline indicates improvement.

End point type	Secondary
----------------	-----------

End point timeframe:

12 and 16 weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	115		
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 12, initiation (n=111,108)	-15.6 (± 7.49)	-13.2 (± 7.36)		
Week 16, initiation (n=109,103)	-16.1 (± 6.80)	-12.3 (± 7.68)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean change from baseline in Dermatology Life Quality Index (DLQI)Total scores - Maintenance 1 Period

End point title	Mean change from baseline in Dermatology Life Quality Index (DLQI)Total scores - Maintenance 1 Period
-----------------	---

End point description:

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases. The measure is widely used: it has been tested across 32 different skin conditions and is available in 55 languages. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative change from baseline indicates improvement.

End point type Secondary

End point timeframe:

16, 24 and 48 weeks

End point values	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	107	66	37	
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 16, maintenance 1 (n=106,64,36)	-16.3 (± 6.67)	-15.9 (± 6.31)	-6.1 (± 5.86)	
Week 24, maintenance 1 (n=102,64,35)	-15.7 (± 7.25)	-14.4 (± 6.73)	-8.7 (± 6.01)	
Week 48, maintenance 1 (n=86, 55, 19)	-16.2 (± 8.06)	-11.5 (± 8.14)	-9.8 (± 6.76)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean change from baseline in Dermatology Life Quality Index (DLQI) Total scores - Maintenance 2 Period

End point title Mean change from baseline in Dermatology Life Quality Index (DLQI) Total scores - Maintenance 2 Period

End point description:

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases. The measure is widely used: it has been tested across 32 different skin conditions and is available in 55 languages. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative change from baseline indicates improvement.

End point type Secondary

End point timeframe:

48 and 72 weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 2)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	83	31	16	24
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 48, maintenance 2 (n=79,30,16,24)	-17.2 (± 7.33)	-14.7 (± 6.19)	-11.5 (± 5.98)	-7.7 (± 8.80)
Week 72, maintenance 2 (n=74,26,12,21)	-17.0 (± 7.27)	-13.0 (± 5.62)	-11.3 (± 4.77)	-15.0 (± 8.76)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Initiation Period

End point title	Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Initiation Period
-----------------	---

End point description:

The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score.

End point type	Secondary
----------------	-----------

End point timeframe:

12 and 16 weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	115		
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 12, initiation(n=110,106)	76.25 (± 18.612)	72.92 (± 20.004)		
Week 16, initiation (n=108,103)	76.30 (± 21.580)	75.25 (± 19.100)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Maintenance 1 Period

End point title	Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Maintenance 1 Period
-----------------	--

End point description:

The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score.

End point type	Secondary
----------------	-----------

End point timeframe:

16, 24 and 48 weeks

End point values	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	107	66	37	
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 16, maintenance 1 (n=105,64,37)	77.33 (± 20.665)	80.48 (± 16.099)	67.03 (± 20.657)	
Week 24, maintenance 1 (n=102,64,35)	79.16 (± 18.587)	80.05 (± 16.345)	69.14 (± 19.587)	
Week 48, maintenance 1 (n=86,55,19)	77.73 (± 21.598)	76.07 (± 20.413)	70.37 (± 18.038)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Maintenance 2 Period

End point title	Mean EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) health state assessment scores (from 0 to 100) - Maintenance 2 Period
-----------------	--

End point description:

The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score.

End point type	Secondary
----------------	-----------

End point timeframe:

48 and 72 weeks

<b>End point values</b>	Secukinumab (AIN457) 300 mg	Secukinumab (AIN457) 150 mg	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 1)	Secukinumab (AIN457) 150 mg - 300 mg (Maintenance period 2)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	83	31	16	24
Units: score on a scale				
arithmetic mean (standard deviation)				
Week 48, maintenance 2 (n=79,30,16,24)	80.22 (± 19.200)	83.87 (± 11.337)	74.50 (± 14.855)	67.63 (± 24.912)
Week 72, maintenance 2 (n=73,26,12,21)	78.24 (± 19.792)	80.88 (± 17.635)	77.67 (± 16.615)	79.67 (± 18.680)

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

### Reporting groups

Reporting group title	Secukinumab 150mg
-----------------------	-------------------

Reporting group description:

Secukinumab 150mg

Reporting group title	Secukinumab 300mg
-----------------------	-------------------

Reporting group description:

Secukinumab 300mg

<b>Serious adverse events</b>	Secukinumab 150mg	Secukinumab 300mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 115 (12.17%)	24 / 179 (13.41%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Diabetic macroangiopathy			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocution			

subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Malaise</b>			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Peripheral swelling</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pyrexia</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Social circumstances</b>			
<b>Pregnancy of partner</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
<b>Blood creatinine increased</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Prostatic specific antigen increased</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>Ankle fracture</b>			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Joint injury			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	2 / 115 (1.74%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Alcoholic seizure			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 115 (0.00%)	2 / 179 (1.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug withdrawal convulsions			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Hypoaesthesia			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic neuritis			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 115 (0.87%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pancreatitis			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 115 (1.74%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis alcoholic			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 115 (0.00%)	2 / 179 (1.12%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash erythematous			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Glomerulonephritis proliferative			

subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 115 (0.00%)	2 / 179 (1.12%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lower respiratory tract infection			
subjects affected / exposed	1 / 115 (0.87%)	2 / 179 (1.12%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	2 / 115 (1.74%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval abscess			
subjects affected / exposed	1 / 115 (0.87%)	0 / 179 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			

subjects affected / exposed	0 / 115 (0.00%)	1 / 179 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	Secukinumab 150mg	Secukinumab 300mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	88 / 115 (76.52%)	152 / 179 (84.92%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 115 (0.00%)	9 / 179 (5.03%)	
occurrences (all)	0	10	
Vascular disorders			
Hypertension			
subjects affected / exposed	8 / 115 (6.96%)	7 / 179 (3.91%)	
occurrences (all)	9	7	
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	3 / 115 (2.61%)	0 / 179 (0.00%)	
occurrences (all)	3	0	
Fatigue			
subjects affected / exposed	9 / 115 (7.83%)	8 / 179 (4.47%)	
occurrences (all)	28	11	
Influenza like illness			
subjects affected / exposed	8 / 115 (6.96%)	7 / 179 (3.91%)	
occurrences (all)	8	10	
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	3 / 115 (2.61%)	6 / 179 (3.35%)	
occurrences (all)	3	6	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	11 / 115 (9.57%)	20 / 179 (11.17%)	
occurrences (all)	11	26	

Dyspnoea subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	4 / 179 (2.23%) 4	
Nasal congestion subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	4 / 179 (2.23%) 5	
Oropharyngeal pain subjects affected / exposed occurrences (all)	9 / 115 (7.83%) 13	29 / 179 (16.20%) 39	
Sleep apnoea syndrome subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 179 (2.23%) 4	
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 7	4 / 179 (2.23%) 4	
Insomnia subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	5 / 179 (2.79%) 5	
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	6 / 179 (3.35%) 6	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	5 / 179 (2.79%) 5	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	6 / 179 (3.35%) 7	
Blood glucose increased subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	3 / 179 (1.68%) 4	
Blood triglycerides increased subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 3	4 / 179 (2.23%) 4	
Gamma-glutamyltransferase			

increased subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	7 / 179 (3.91%) 7	
Lipase increased subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	6 / 179 (3.35%) 6	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 3	4 / 179 (2.23%) 5	
Fall subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	7 / 179 (3.91%) 10	
Joint injury subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	3 / 179 (1.68%) 3	
Limb injury subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 179 (2.23%) 4	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	9 / 179 (5.03%) 9	
Headache subjects affected / exposed occurrences (all)	27 / 115 (23.48%) 57	28 / 179 (15.64%) 44	
Lethargy subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 4	5 / 179 (2.79%) 6	
Migraine subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 5	2 / 179 (1.12%) 3	
Paraesthesia subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 4	2 / 179 (1.12%) 3	
Eye disorders			

Dry eye subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	5 / 179 (2.79%) 6	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	4 / 179 (2.23%) 4	
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	5 / 179 (2.79%) 6	
Diarrhoea subjects affected / exposed occurrences (all)	14 / 115 (12.17%) 17	16 / 179 (8.94%) 21	
Dyspepsia subjects affected / exposed occurrences (all)	7 / 115 (6.09%) 7	7 / 179 (3.91%) 7	
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 179 (2.23%) 4	
Mouth ulceration subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	5 / 179 (2.79%) 5	
Nausea subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 11	19 / 179 (10.61%) 21	
Toothache subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	2 / 179 (1.12%) 6	
Vomiting subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 8	12 / 179 (6.70%) 12	
Skin and subcutaneous tissue disorders			
Eczema subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 4	5 / 179 (2.79%) 6	
Hyperhidrosis			

subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 179 (2.23%) 4	
Intertrigo subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	2 / 179 (1.12%) 3	
Pruritus subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 4	4 / 179 (2.23%) 7	
Pruritus generalised subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 5	1 / 179 (0.56%) 1	
Psoriasis subjects affected / exposed occurrences (all)	15 / 115 (13.04%) 17	28 / 179 (15.64%) 36	
Rash subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	6 / 179 (3.35%) 7	
Urticaria subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	1 / 179 (0.56%) 1	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	9 / 115 (7.83%) 16	19 / 179 (10.61%) 25	
Arthritis subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	2 / 179 (1.12%) 2	
Back pain subjects affected / exposed occurrences (all)	8 / 115 (6.96%) 8	16 / 179 (8.94%) 22	
Joint swelling subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	9 / 179 (5.03%) 9	
Musculoskeletal pain			

subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	4 / 179 (2.23%) 7	
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 4	0 / 179 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 2	8 / 179 (4.47%) 9	
Neck pain subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 2	5 / 179 (2.79%) 5	
Pain in extremity subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	11 / 179 (6.15%) 15	
Tendonitis subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	0 / 179 (0.00%) 0	
Infections and infestations			
Cellulitis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 179 (2.23%) 4	
Conjunctivitis subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 3	7 / 179 (3.91%) 9	
Ear infection subjects affected / exposed occurrences (all)	7 / 115 (6.09%) 10	7 / 179 (3.91%) 8	
Folliculitis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	4 / 179 (2.23%) 4	
Gastroenteritis subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	3 / 179 (1.68%) 3	
Influenza subjects affected / exposed occurrences (all)	5 / 115 (4.35%) 5	9 / 179 (5.03%) 10	

Lower respiratory tract infection subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 7	14 / 179 (7.82%) 16
Nasopharyngitis subjects affected / exposed occurrences (all)	27 / 115 (23.48%) 41	52 / 179 (29.05%) 69
Oral candidiasis subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 3	7 / 179 (3.91%) 12
Oral herpes subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 6	5 / 179 (2.79%) 6
Otitis externa subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 5	2 / 179 (1.12%) 7
Pharyngitis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	5 / 179 (2.79%) 5
Sinusitis subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	12 / 179 (6.70%) 17
Tinea pedis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	4 / 179 (2.23%) 4
Tonsillitis subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	3 / 179 (1.68%) 3
Upper respiratory tract infection subjects affected / exposed occurrences (all)	8 / 115 (6.96%) 9	9 / 179 (5.03%) 9
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 7	10 / 179 (5.59%) 14
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 13	11 / 179 (6.15%) 16

Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	6 / 115 (5.22%) 8	8 / 179 (4.47%) 13	
Metabolism and nutrition disorders			
Diabetes mellitus subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	0 / 179 (0.00%) 0	
Gout subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	1 / 179 (0.56%) 1	
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	4 / 115 (3.48%) 4	2 / 179 (1.12%) 2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 August 2013	The main purpose of this amendment was that female patients were required to use two effective forms of contraception and male patients were required to use one effective form of contraception
28 November 2013	The main purposes of this amendment were the primary endpoint was changed from 12 weeks to 16 weeks; 12 weeks efficacy was included as a secondary endpoint; the option of up titration at for patients on the 150mg dose secukinumab to 300mg if they were not achieving the NICE criteria; and administrative changes.
03 July 2014	The main purpose of this amendment was to further evaluate: secukinumab safety, efficacy and tolerability for a further 24 weeks; patient response in those patients not achieving adequate efficacy on 150mg secukinumab at Week 48, when up-titrated to 300mg; PASI 50, 75 and 90 response at 24, 48 and 72 weeks; and previous exposure to Ustekinumab no longer an exclusion criteria.
22 February 2016	Minor administrative updates were made to the protocol including: an updated author and steering committee list; minor corrections to the numbering of days for maintenance period 2; Updates to the patient exposure and post-marketing experience information; Update to the use of the results and interim analysis; Clarification on the acceptable duration of concomitant mild-moderate topical steroids; Clarification on prohibited meds; Correction to the description of the statistical model, hypothesis and method of analysis section

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported